Compare · NVO vs SER
NVO vs SER
Side-by-side comparison of Novo Nordisk A/S (NVO) and Serina Therapeutics Inc. (SER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SER operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 6803.1x SER ($28.2M).
- SER has been more active in the news (9 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for SER).
- Company
- Novo Nordisk A/S
- Serina Therapeutics Inc.
- Price
- -
- -
- Market cap
- $191.82B
- $28.2M
- 1M return
- -8.54%
- -
- 1Y return
- -44.51%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2018
- News (4w)
- 8
- 9
- Recent ratings
- 25
- 1
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest SER
- SEC Form EFFECT filed by Serina Therapeutics Inc.
- Chief Executive Officer Ledger Steven A was granted 10,100 shares (SEC Form 4)
- SEC Form 4 filed by SVP, CMC & Formulation Tenjarla Srini
- SEC Form 4 filed by Chief Executive Officer Ledger Steven A
- SEC Form 4 filed by Chief Financial Officer Curhan Gregory S
- SEC Form 4 filed by Chief Scientific Officer Moreadith Randall
- Director Wilson Karen J bought $37,000 worth of shares (20,000 units at $1.85) (SEC Form 4)
- Director Marshall Richard Peter bought $20,102 worth of shares (12,183 units at $1.65) (SEC Form 4)
- SEC Form S-3 filed by Serina Therapeutics Inc.
- Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates